These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 30688730)

  • 1. Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT.
    Nobashi T; Baratto L; Reddy SA; Srinivas S; Toriihara A; Hatami N; Yohannan TK; Mittra E
    Clin Nucl Med; 2019 Apr; 44(4):e272-e279. PubMed ID: 30688730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive
    Schwenck J; Schörg B; Fiz F; Sonanini D; Forschner A; Eigentler T; Weide B; Martella M; Gonzalez-Menendez I; Campi C; Sambuceti G; Seith F; Quintanilla-Martinez L; Garbe C; Pfannenberg C; Röcken M; la Fougere C; Pichler BJ; Kneilling M
    Theranostics; 2020; 10(2):925-937. PubMed ID: 31903160
    [No Abstract]   [Full Text] [Related]  

  • 3.
    Eshghi N; Garland LL; Nia E; Betancourt R; Krupinski E; Kuo PH
    J Nucl Med Technol; 2018 Sep; 46(3):260-264. PubMed ID: 29599403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of quantitative imaging biomarkers in an early FDG-PET/CT for detection of immune-related adverse events in melanoma patients: a prospective study.
    Hribernik N; Strasek K; Huff DT; Studen A; Zevnik K; Skalic K; Jeraj R; Rebersek M
    Radiol Oncol; 2024 Sep; 58(3):335-347. PubMed ID: 39287171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorine-18 fluorodeoxyglucose uptake change in liver, mediastinal blood pool, and lymphoid cell-rich organs during programmed cell death-1 immunotherapy in lymphoma.
    Guo L; Wang R; Shen G
    Nucl Med Commun; 2024 Aug; 45(8):718-726. PubMed ID: 38726632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study.
    Hribernik N; Huff DT; Studen A; Zevnik K; Klaneček Ž; Emamekhoo H; Škalic K; Jeraj R; Reberšek M
    Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1857-1869. PubMed ID: 34958422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT.
    Wachsmann JW; Ganti R; Peng F
    Acad Radiol; 2017 Jan; 24(1):111-115. PubMed ID: 27818005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.
    Iravani A; Osman MM; Weppler AM; Wallace R; Galligan A; Lasocki A; Hunter MO; Akhurst T; Hofman MS; Lau PKH; Kee D; Au-Yeung G; Sandhu S; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2776-2786. PubMed ID: 32338306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET/CT metabolic patterns in systemic immune activation: A new perspective on the assessment of immunotherapy response and efficacy.
    Jin P; Li J; Meng Y; Wu L; Bai M; Yu J; Meng X
    Cancer Lett; 2021 Nov; 520():91-99. PubMed ID: 34237407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point
    Cho SY; Lipson EJ; Im HJ; Rowe SP; Gonzalez EM; Blackford A; Chirindel A; Pardoll DM; Topalian SL; Wahl RL
    J Nucl Med; 2017 Sep; 58(9):1421-1428. PubMed ID: 28360208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic impact of
    Tatar G; Alçin G; Sengul Samanci N; Erol Fenercioglu Ö; Beyhan E; Cermik TF
    Clin Transl Oncol; 2022 Oct; 24(10):1903-1913. PubMed ID: 35594002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
    Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
    J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment response evaluation with
    Sachpekidis C; Hillengass J; Goldschmidt H; Wagner B; Haberkorn U; Kopka K; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):50-62. PubMed ID: 27573638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitors in Advanced NSCLC: [
    Ferrari C; Santo G; Merenda N; Branca A; Mammucci P; Pizzutilo P; Gadaleta CD; Rubini G
    Diagnostics (Basel); 2021 Sep; 11(9):. PubMed ID: 34574022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Utility of
    Chen H; Jin R; Wang Y; Li L; Li K; He Y
    Biomed Res Int; 2018; 2018():1823710. PubMed ID: 29686996
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Dercle L; Seban RD; Lazarovici J; Schwartz LH; Houot R; Ammari S; Danu A; Edeline V; Marabelle A; Ribrag V; Michot JM
    J Nucl Med; 2018 Jan; 59(1):15-24. PubMed ID: 28596157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients.
    Mayerhoefer ME; Karanikas G; Kletter K; Kiesewetter B; Weber M; Rausch I; Pones M; Simonitsch-Klupp I; Müllauer L; Dolak W; Lukas J; Raderer M
    Clin Nucl Med; 2016 Nov; 41(11):837-843. PubMed ID: 27648705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
    Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
    J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does dual-time-point
    Wu B; Zhao Y; Zhang Y; Tan H; Shi H
    Hell J Nucl Med; 2017; 20(1):79-82. PubMed ID: 28315913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of 18F-FDG PET/CT for evaluating response of ocular adnexal lymphoma to treatment.
    Fujii H; Tanaka H; Nomoto Y; Harata N; Oota S; Isogai J; Yoshida K
    Medicine (Baltimore); 2018 Apr; 97(17):e0543. PubMed ID: 29703034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.